Immune Checkpoint Inhibitors Market - Trends Forecast Till 2028

Market Overview

The global immune checkpoint inhibitors market is anticipated to reach USD 38.5 billion by 2020 growing at a CAGR of 18.7% during the forecasting period, 2020-2028. Immune checkpoint inhibitors are a kind of drug which has been used in immunotherapy that helps in targeting cell surface checkpoint proteins for stimulating the recognition and destruction of cancer cells by the immune system. Factors such as the rising prevalence of cancer and raising awareness of immune checkpoint inhibitors are some of the major drivers for the immune checkpoint inhibitors market

Key Findings

The global immune checkpoint inhibitors market is segmented into type, therapeutic application, treatment, application, end-user, and geography.

The type segment is segmented into PD-1, PD-L1 Inhibitors, CLTA-4 Inhibitors, Elotuzumab, INCB024360, Indoximod, Lirilumab. PD-1 segment is further segmented into PEMBROLIZUMAB (KEYTRUDA), NIVOLUMAB (OPDIVO), CEMIPLIMAB (LIBTAYO). PD-L1 is segmented into DURVALUMAB (IMFINZI), AVELUMAB (BAVENCIO), and ATEZOLIZUMAB (TECENTRIQ).

Therapeutic Application segment is segmented into Lung Cancer, Melanoma Squamous Cell Carcinoma, Urothelial Carcinoma, Blood Cancer and Others

End Users segment is segmented into Hospitals, Specialty Clinics, Oncology Centers and Others

Distribution Channel segment is segmented into Hospital Pharmacies and Retail Pharmacies

Geographically, the global immune checkpoint inhibitors market is sub-segmented into North America, Europe, Asia-Pacific, Middle East and Africa and South America, and insights are provided for each region and major countries within the regions 

Regional Analysis

North America region is the largest contributor to the immune checkpoint inhibitors market in the forecast period 2020-2028 and the Asia-Pacific region is expected to grow with the highest CAGR during the forecast period 2020-2028.

Competitive Landscape

Key players in the global immune checkpoint inhibitors market are Bristol-Myers Squibb Company, AstraZeneca PLC., Eli Lilly and Company, Fortress Biotech, Inc., F. Hoffmann-La Roche Ltd. Immutep Limited, Merck & Co., Inc., Merck KGaA, Novartis AG, Pfizer Inc. among others

Recent Developments

The companies have come up with various promotional activities in from of launch, investment, acquisition, and other, for instance:

• In 2018, Bristol-Myers Squibb Company has announced the collaboration with the Vedanta Biosciences for evaluating Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor
• In 2018, Kite, a Gilead Company has announced a collaboration with the Sangamo Therapeutics for modifying the genes through Sangamo Therapeutics’ zinc finger nuclease (ZFN) gene-editing technology platform to develop autologous and allogeneic next-generation ex vivo cell therapies for different cancers

Hence, tremendous progress has been made over the last decade, and yet a lot more to come in recent years.

Reasons to Acquire

• Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors
• Gain authentic and granular data access for the immune checkpoint inhibitors market so as to understand the trends and the factors involved in changing market situations
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

Report Scope